Last reviewed · How we verify
high-dose ranibizumab
At a glance
| Generic name | high-dose ranibizumab |
|---|---|
| Sponsor | Hawaii Pacific Health |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Zifibancimig in Participants With Neovascular Age-related Macular Degeneration (PHASE1, PHASE2)
- A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME (PHASE2, PHASE3)
- CLN-0046: Treatment of AMD Subjects With OTX-TKI (PHASE1)
- A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration (PHASE2)
- Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy (PHASE1, PHASE2)
- Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects (PHASE2)
- A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |